GlobeNewswire

Compuware zAdviser Delivers Actionable Analytic Insight to Continuously Improve Quality, Velocity and Efficiency on the Mainframe

Dela

Innovative Machine Learning Helps IT Leaders Pinpoint Opportunities to Boost DevOps Processes and Development Outcomes

 
  • Enterprises dependent on mainframe applications must aggressively improve DevOps quality, velocity and efficiency-even as responsibilities shift to less experienced internal teams and/or outsourcing partners.

  • Compuware is introducing zAdviser, a free product that leverages machine learning to help IT leaders make smarter data-driven decisions to drive continuous improvement of mainframe DevOps.

  • zAdviser identifies patterns that impact quality, velocity and efficiency as they pertain to mainframe development by analyzing a customer's Compuware product usage data and DevOps key performance indicators (KPIs).  

  • zAdviser is fueled by the ongoing collaboration between customers and Compuware, where customers contribute their relevant DevOps data and Compuware contributes their mainframe expertise and machine learning insights.

DETROIT, April 03, 2018 (GLOBE NEWSWIRE) -- Compuware today announced zAdviser, an innovative product that uses machine learning to continuously measure and improve an organization's mainframe DevOps processes and development outcomes. Based on key performance indicators (KPIs), zAdviser measures application quality, as well as development velocity and the efficiency of a development team-empowering enterprise IT leaders to make evidence-based decisions in support of their continuous improvement efforts. zAdviser is free for Compuware customers on current maintenance.

The KPIs were developed based on extensive research with customers and align with those published in the 2018 Forrester report, "Use Four Key Categories To Measure What Matters In Continuous Deployment."

zAdviser leverages a set of analytic models that uncover correlations between mainframe developer behaviors and mainframe DevOps KPIs. These correlations represent the best available empirical evidence regarding the impact of process, training and tooling decisions on digital business outcomes. With this empirical evidence and associated recommendations, managers can make high-impact decisions about their mainframe DevOps methods with vastly improved speed and confidence.

Enterprises that outsource mainframe development can also reap significant value from zAdviser by using the analytical results to continuously achieve better business outcomes over time.

Improvements in mainframe DevOps is an imperative for large enterprises, which are becoming more dependent on mainframe applications-not less. According to a recent Forrester Consulting study commissioned by Compuware, 57 percent of enterprises with a mainframe run more than half of their business-critical workloads on the platform. That percentage is expected to increase to 64 percent by 2019, while at the same time enterprises are failing to replace the expert mainframe workforce they have lost by attrition.

According to the study, "As mainframe workload increases-driven by modern analytics, blockchain and more mobile activity hitting the platform-customer-obsessed companies should seek to modernize application delivery and remove roadblocks to innovation."

The Forrester Consulting study also highlights the importance of responding to these challenges with empirical insight: "KPIs like mean lead time, number of epics per deployment, and metrics that drive automation will harness velocity and efficiency, even as the skills gap of the workforce expands." The full study can be accessed here.

Compuware has been helping their customers qualify, quantify and increase the value derived from their Compuware products through its Value Improvement Program (VIP) for over 15 years. zAdviser is the next step in the evolution of the VIP and evidence-based mainframe process improvement, leveraging these years of experience helping enterprises modernize mainframe DevOps and improve mainframe staff performance.

zAdviser data inputs include both 1) metrics captured from Compuware tools, including behavioral data relating to feature utilization and 2) data captured from the customer's DevOps toolchain.

By aggregating input from customer sites across industries and around the world, Compuware is building the industry's richest repository of mainframe DevOps data-which combined with advanced machine learning methods generates unmatched insight for enterprise IT leaders.

"Our mainframe applications continue to play a critical role in delivering an excellent customer experience," said Steve Kalkowski, Assistant Vice President, The Hartford. "A product like Compuware zAdviser will give us the advanced analytics we need to drive our efforts towards improving developer speed and quality as we transition to an agile delivery model."

Compuware today also announced a new ThruPut Manager web interface that provides mainframe staff with visually intuitive insight into how batch jobs are being initiated and executed-as well as the impact of those jobs on mainframe software licensing costs.

"Enterprises cannot afford to be even slightly complacent about the speed and excellence with which they update and evolve the core business logic of their mainframe applications," said Compuware CEO Chris O'Malley. "With zAdviser, Compuware is now offering a powerful, fact-based resource for IT leaders at the world's largest corporations to lead their critical mainframe modernization efforts-and to thereby sustainably derive maximum business value from their investments in mainframe hardware, applications and talent."

To learn more about zAdviser and get involved, visit us here.

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com .

Follow us on:

Press Contact
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-266-7892, www.compuware.com.

Copyright © 2018, Compuware Corporation. All rights reserved. The Compuware products and services listed within this release are trademarks or registered trademarks of Compuware Corporation.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen

Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum